Pulmonx Corp
LUNGNasdaq
$1.40
↓ -3.4%Jul 17 close · end-of-day
Price
1Y↓ -51.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$58.7M
Enterprise Value
$34.4M
P/E
—
P/S
0.7
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
-50.1%
Dividend Yield
—
Revenue (TTM)
$88.5M
Net Income (TTM)
-$53.2M
Free Cash Flow (TTM)
-$29.4M
Gross Margin
75.5%
Operating Margin
-58.8%
Net Margin
-60.1%
ROE
-116.3%
ROIC
-191.3%
Debt / Equity
0.8
Net Cash
$24.3M
Return 1Y
-54.7%
Company profile
Pulmonx Corporation provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service. It serves emphysema patients in the United States, Europe, the Middle East, Africa, Asia-Pacific and internationally.
- CEO
- Glendon E. French
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 250
- Headquarters
- California
- Website
- pulmonx.com
Management & directors
- French Glendon E. IiiPresident and CEO
- Lehman David AaronGENERAL COUNSEL
- Radhakrishnan SrikanthChief Science &Techn. Officer
- Rose Geoffrey BeranCHIEF COMMERCIAL OFFICER
- Sung DerrickCOO and CFO
- Joshi MehulChief Financial Officer & PAO
- Williamson Steve SPRESIDENT AND CEO
Roles derived from SEC Form 4 filings.
Earnings
LUNG Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.6M↓ -8.7%
Diluted EPS-$0.33↓ -8.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $32.7M | $48.4M | $53.7M | $68.7M | $83.8M | $90.5M |
| Gross profit | $21.2M | $35.6M | $39.9M | $50.8M | $62.0M | $67.1M |
| Operating income | -$32.3M | -$47.3M | -$58.6M | -$61.9M | -$57.7M | -$53.7M |
| Net income | -$32.2M | -$48.7M | -$58.9M | -$60.8M | -$56.4M | -$54.0M |
| Diluted EPS | -$3.16 | -$1.35 | -$1.59 | -$1.60 | -$1.44 | -$1.33 |
| Operating cash flow | -$30.6M | -$41.4M | -$45.1M | -$37.6M | -$31.5M | -$32.4M |
| Free cash flow | -$31.5M | -$45.1M | -$46.4M | -$38.4M | -$33.0M | -$32.8M |
| Gross margin | 64.8% | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Operating margin | -98.8% | -97.7% | -109.3% | -90.2% | -68.9% | -59.3% |
| Net margin | -98.5% | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.8M | $20.4M | $23.8M | $22.5M | $23.9M | $21.5M | $22.6M | $20.6M |
| Gross profit | $15.3M | $15.0M | $17.6M | $16.3M | $17.2M | $16.1M | $17.5M | $16.0M |
| Operating income | -$15.6M | -$14.1M | -$13.4M | -$14.6M | -$14.8M | -$14.4M | -$9.9M | -$13.0M |
| Net income | -$15.3M | -$14.1M | -$13.2M | -$14.4M | -$15.2M | -$14.0M | -$10.4M | -$13.7M |
| Diluted EPS | -$0.39 | -$0.36 | -$0.33 | -$0.36 | -$0.38 | -$0.34 | -$0.25 | -$0.33 |
| Operating cash flow | -$5.8M | -$7.2M | -$6.7M | -$13.2M | -$3.9M | -$8.2M | -$7.1M | -$10.1M |
| Free cash flow | -$6.2M | -$7.7M | -$6.8M | -$13.5M | -$4.0M | -$8.3M | -$7.1M | -$10.1M |
| Gross margin | 73.7% | 73.7% | 74.0% | 72.5% | 72.1% | 74.7% | 77.6% | 77.9% |
| Operating margin | -75.2% | -69.3% | -56.5% | -64.6% | -62.0% | -66.9% | -43.8% | -62.9% |
| Net margin | -73.7% | -69.4% | -55.4% | -64.1% | -63.6% | -64.9% | -46.1% | -66.3% |
Company news
Jul 15, 2026
Apr 30, 2026
Apr 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | Sullivan Tiffany | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Burns Thomas William | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | FERRARI RICHARD M | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Florin Daniel P | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Melenikiotou Georgia | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Mead Dana G Jr. | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-06-02 | French Glendon E. III· President and CEO | Sale | 13,511 | $1.57 | $21,212.27 | filing |
| 2026-06-01 | French Glendon E. III· President and CEO | Sale | 38,467 | $1.54 | $59,239.18 | filing |
| 2026-06-01 | Radhakrishnan Srikanth· Chief Science &Techn. Officer | Sale | 5,969 | $1.54 | $9,192.26 | filing |
| 2026-06-01 | Lehman David Aaron· GENERAL COUNSEL | Sale | 4,915 | $1.54 | $7,569.10 | filing |
| 2026-06-01 | French Glendon E. III· President and CEO | Sale | 4,171 | $1.54 | $6,423.34 | filing |
| 2026-06-01 | Lehman David Aaron· GENERAL COUNSEL | Sale | 3,876 | $1.54 | $5,969.04 | filing |
| 2026-06-01 | Radhakrishnan Srikanth· Chief Science &Techn. Officer | Sale | 3,684 | $1.54 | $5,673.36 | filing |
| 2026-06-01 | Lehman David Aaron· GENERAL COUNSEL | Sale | 3,539 | $1.54 | $5,450.06 | filing |
| 2026-06-01 | Radhakrishnan Srikanth· Chief Science &Techn. Officer | Sale | 2,691 | $1.54 | $4,144.14 | filing |
| 2026-06-01 | Rose Geoffrey Beran· CHIEF COMMERCIAL OFFICER | Sale | 2,434 | $1.54 | $3,748.36 | filing |
| 2026-06-01 | Lehman David Aaron· GENERAL COUNSEL | Sale | 2,264 | $1.54 | $3,486.56 | filing |
| 2026-06-01 | Rose Geoffrey Beran· CHIEF COMMERCIAL OFFICER | Sale | 2,254 | $1.54 | $3,471.16 | filing |
| 2026-06-01 | Radhakrishnan Srikanth· Chief Science &Techn. Officer | Sale | 2,153 | $1.54 | $3,315.62 | filing |
| 2026-06-01 | Rose Geoffrey Beran· CHIEF COMMERCIAL OFFICER | Sale | 1,778 | $1.54 | $2,738.12 | filing |
| 2026-06-01 | Rose Geoffrey Beran· CHIEF COMMERCIAL OFFICER | Sale | 1,557 | $1.54 | $2,397.78 | filing |
| 2026-03-02 | French Glendon E. III· President and CEO | Sale | 58,368 | $1.43 | $83,466.24 | filing |
| 2026-03-02 | French Glendon E. III· President and CEO | Sale | 6,737 | $1.43 | $9,633.91 | filing |
| 2026-03-02 | Lehman David Aaron· GENERAL COUNSEL | Sale | 4,433 | $1.43 | $6,339.19 | filing |
| 2026-03-02 | Radhakrishnan Srikanth· Chief Science &Techn. Officer | Sale | 4,198 | $1.43 | $6,003.14 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.